Responses
Cardiovascular and metabolic risk
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
Compose a Response to This Article
Other responses
No responses have been published for this article.